Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis

被引：0

作者：

Mauro Zaffaroni

Annalisa Rizzo

Silvana Maria Baldini

Angelo Ghezzi

Giancarlo Comi

机构：

[1] Centro Studi Sclerosi Multipla,

[2] S. Raffaele Hospital and University,undefined

来源：

Neurological Sciences | 2008年 / 29卷

关键词：

Interferon beta; Glatiramer acetate; Mitoxantrone; Combination therapy; Induction therapy; Rescue therapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-β (IFN-β) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/ persistently active disease in spite of IFN-β (add-on/combination therapy), or for increased disability suggesting a secondary progression (rescue therapy). After almost 2-year follow-up, relapse rate and disability decreased very significantly in the two former groups while MX was essentially ineffective as rescue therapy. Induction therapy is a valid option for very aggressive/active CIS and MS at onset.

引用

页码：230 / 232

页数：2

共 50 条

[1] Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis
Zaffaroni, Mauro
Rizzo, Annalisa
Baldini, Silvana Maria
Ghezzi, Angelo
Comi, Giancarlo
NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 2) : S230 - S232
[2] Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease
Greenberg, Steven J.
Zivadinov, Robert
Lee-Kwen, Peterkin
Sharma, Jitendra
Planter, Margaret
Umhauer, Margaret
Glenister, Norman
Bakshi, Rohit
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (02) : 105 - 117
[3] Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis
Vollmer, T.
Panitch, H.
Bar-Or, A.
Dunn, J.
Freedman, M. S.
Gazda, S. K.
Campagnolo, D.
Deutsch, F.
Arnold, D. L.
MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (05) : 663 - 670
[4] Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis
Ticha, Veronika
Kalincik, Tomas
Havrdova, Eva
NEUROLOGICAL RESEARCH, 2012, 34 (10) : 923 - 930
[5] Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
Sorensen, Per Soelberg
Lycke, Jan
Eralinna, Juha-Pekka
Edland, Astrid
Wu, Xingchen
Frederiksen, Jette Lautrup
Oturai, Annette
Malmestrom, Clas
Stenager, Egon
Sellebjerg, Finn
Sondergaard, Helle Bach
LANCET NEUROLOGY, 2011, 10 (08) : 691 - 701
[6] Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis
Ytterberg, C.
Johansson, S.
Anderson, M.
Olsson, D.
Link, H.
Holmqvist, L. W.
von Koch, L.
ACTA NEUROLOGICA SCANDINAVICA, 2007, 116 (02): : 96 - 99
[7] Mitoxantrone in the therapy of multiple sclerosis
Kieseier, BC
Gold, R
Neuhaus, O
Hartung, HP
NERVENARZT, 2003, 74 (10): : 906 - 910
[8] Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis
Neuhaus, Oliver
Kieseier, Bernd C.
Hartung, Hans-Peter
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2007, 259 (1-2) : 27 - 37
[9] Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis
Bertolotto, A
CURRENT OPINION IN NEUROLOGY, 2004, 17 (03) : 241 - 246
[10] Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis
María Isabel Carrasco-Campos
Cristina Pérez-Ramírez
Elena Macías-Cortés
Elena Puerta-García
Antonio Sánchez-Pozo
Carmen Arnal-García
Francisco Javier Barrero-Hernández
Miguel Ángel Calleja-Hernández
Alberto Jiménez-Morales
Marisa Cañadas-Garre
Molecular Neurobiology, 2021, 58 : 4716 - 4726

← 1 2 3 4 5 →